Clinical trials of CTL019 anti-CD19 CAR-T therapy showed a severe CRS occurrence rate of 29% in B-ALL, 39% in B-CLL, and 20% in B-non-Hodgkin’s lymphoma patients, although BCMA-targeting CAR-T included a grade 3/4 CRS occurrence rate of 6% (all grades 76%) in a bb212 trial and 7% (all grades 90%) in a LCAR-B38M trial. This evidence concerns the gene CD19 and precursor B-cell acute lymphoblastic leukemia.